Commercial Regeneron Q1 2026 net income falls 10% to $727m Pharmaceutical Business ReviewOn a non-GAAP basis, net income rose 12% to $1.04bn from $928m.Read full story pharminent April 30, 2026 (Last updated: April 30, 2026) Pharmaceutical Business Review On a non-GAAP basis, net income rose 12% to $1.04bn from $928m. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Ray Therapeutics receives EMA PRIME status for gene therapyNext: Norgine gets first EU approval for WHIM syndrome therapy Related Stories Commercial Lilly UK recruits ex-England cricketer as obesity champion pharminent May 15, 2026 Commercial A year after Vertex’s big launch, pain drug research faces a pivotal moment pharminent May 12, 2026 Commercial Daiichi takes $850M charge, axes facility investment as ADC demand forecast falls pharminent May 11, 2026
